Professional
Added to YB: 2025-07-03
Pitch date: 2025-06-30
HLVX [neutral]
HilleVax, Inc.
+4.5%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.
Market Cap
$102.5M
Pitch Price
$2.00
Price Target
2.50 (+20%)
Dividend
N/A
EV/EBITDA
0.70
P/E
-1.45
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Clark Street Value Mid Year 2025 Portfolio Review: Current Position - HilleVax, Inc.
HLVX (holding update): Failed development July 2023, exploring strategic alternatives. Est. liquidation value ~$2.50/share vs $1.90 current price. Key holders: Frazier (21%), Takeda (13.5%), Tang (<10%). Risk: may pursue adult vaccine development despite infant trial failure.
Read full article (1 min)